Women’s health supplement
-
Delivering evidence for a potential new “standard of care” in women’s health.
A nutritional supplement for the “watch and wait” observation period after persistent abnormal Pap smear results caused by HPV
The Opportunity
For thousands of women, a Pap smear test can indicate the presence of HPV-related abnormal cells, which can be a precursor to cancer and other reproductive organ ailments. This is often followed by a “watch and wait” observation period of 6 to 12 months to determine if the cells remain persistently abnormal and require active treatment. Papillex is an evidence-based supplement designed to proactively support the immune system during the “watch and wait” period.
The Challenge
Women with persistently abnormal pap smear results are at risk of developing cervical cancer. Proper screening and vaccines help prevent cervical cancer from developing, but once high-risk abnormal cells from HPV are present, there are no recommended non-surgical options available to women during “watch and wait” observation. The individual ingredients in Papillex have human clinical trials to support their use for cervical dysplasia, and when combined in this patented formulation, the ingredients have been shown to have a synergistic effect. Customers have shared thousands of positive testimonials, and an observational study showed promising results, with seven out of eight participants experiencing improvements in HPV-related cervical changes. Larger clinical trials are essential to substantiate health claims for Papillex and move it closer to becoming a standard recommendation for the thousands of women in the “watch and wait” observation period with persistent HPV.
We are determined to help bring this evidence-based solution to women everywhere who can benefit from it. NPC’s support for our clinical trial brings us a giant step closer to that goal.
NPC’s Solution
NPC provided $250,000 through its Proof of Concept Program to help Papillex complete an extensive randomized, double-blind, placebo-controlled clinical trial. At time of publishing, the trial was at the earliest stage of candidate recruitment. Positive results will help Papillex achieve regulatory approval for their claims, and help guide the adoption of this powerful supplement as a proven and viable option for healthcare practitioners.
NPC is committed to the creation of natural products that are better for people, animals and the planet. We propel early-stage Canadian innovators with the advice, connections and capital they need to develop and de-risk their solutions quickly and efficiently.
Papillex
Description:
Sector(s):
Food, Nutrition, FoodtechFunding Type:
Proof of ConceptProvince:
OntarioFunding Amount:
$250,000
Year of Funding:
2024Name:
Dr. Elizabeth Goldspink